Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EG-COVID-003
- Development stage
- Unknown
- Lead developer
- EyeGene
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
EG-COVID-003 is an mRNA-based vaccine developed by EyeGene Inc. for the prevention of COVID-19. Unlike the lipid nanoparticle (LNP) delivery systems used by Pfizer/BioNTech and Moderna, EG-COVID-003 utilizes a cationic liposome-based drug delivery system that is free of polyethylene glycol (PEG), potentially reducing the risk of anaphylactic reactions. The vaccine encodes the surface antigen (spike protein) of the SARS-CoV-2 virus. A key advantage of this candidate is its freeze-dried formulation, which allows for storage and distribution at standard refrigeration temperatures (2-8°C), bypassing the need for ultra-cold chain logistics. It has progressed into Phase 1/2a clinical trials in South Korea.
- Other names
- EG-COVID
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on EG-COVID-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EG-COVID-003.